Skip to main content
S&P 5007,568.92+0.36%DOW51,786.72-0.38%NASDAQ25,372.01+0.83%BTC$76,850.00-0.36%ETH$2,261.28+0.13%GOLD$3,968.20+0.71%OIL$95.60-0.51%
Smart Investors Daily
SID Premium
NX

NASDAQ · NXL

Nexalin Technology, Inc.

Healthcare · Medical - Devices

$1.54

Up+$0.04 (+2.33%)

Updated Nov 4, 2026, 6:21 AM

SID Score

5.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
18.08M
P/E ratio
-1.99
Dividend yield
0.00%
52-week range
$0.31 – $10.98
Volume
9.88K
Avg. volume
3.55M

Price performance · NXL

NXL price history

1M range · 0 trading sessions · Daily adjusted prices

NXL does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest NXL news

The latest Smart Investors Daily articles mentioning NXL.

Stock researchCompany · Overview

NXL research

Overview

Company profile and research snapshot.

Company profile

Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$4.08
Implied upside
—
Analysts
5
NXL recent ratings
DateFirmRatingTarget
Mar 24, 2025Maxim GroupBuy—
Dec 5, 2024Maxim GroupHold—
Oct 9, 2024Maxim GroupBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 27, 2026

Nexalin Technology Announces Fourth Peer-Reviewed Publication in Alzheimer's Disease: 15 mA DIFS™ Significantly Improves Sleep Quality in Patients with Mild Alzheimer's Disease

Results from the randomized, double-blind, sham-controlled TRANSFORM-AD study published in the Journal of Alzheimer's Disease, a recognized international peer-reviewed journal Statistically significant improvement in sleep quality versus sham (p < 0.001) with no serious adverse events; authors describe the study as the first to evaluate high-intensity stimulation for neuropsychiatric symptoms in Alzheimer's disease HOUSTON, TX, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq:

Yahoo · Oct 8, 2026

Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing

Company remains focused on its transition toward commercial revenue generation and the advancement of its U.S. clinical programsHOUSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has received written confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the minimum bid price r

ChartMill · Oct 2, 2026

Friday's session: top gainers and losers

Intrigued by the market activity one hour before the close of the markets on Friday? Uncover the key winners and losers of today's session in our insightful analysis.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By